FDA accepts Revolution Medicines NDA for daraxonrasib in pancreatic cancer
Revolution Medicines, Inc. (Nasdaq: RVMD) announced that the U.S. Food and Drug Administration accepted for review the company's New Drug ...
(Premium-only article. Please sign in or upgrade to SI Premium to view.)
(Premium-only article. Please sign in or upgrade to SI Premium to view.)
